+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuroendocrine Carcinoma"

Stomach Cancer Market - Product Thumbnail Image

Stomach Cancer Market

  • Report
  • September 2025
  • 150 Pages
  • Global
From
Targeted Radionuclide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Thumbnail Image

Targeted Radionuclide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • September 2025
  • 150 Pages
  • Global
From
Antitumor Peptide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Thumbnail Image

Antitumor Peptide Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • July 2025
  • 150 Pages
  • Global
From
Radioligand Therapy (RlT) Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapeutic Application, Targeted Ligands, End User, Radioligand Type - Product Thumbnail Image

Radioligand Therapy (RlT) Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapeutic Application, Targeted Ligands, End User, Radioligand Type

  • Report
  • January 2026
  • 160 Pages
  • Global
From
DLL3-Targeted Immunotherapy: a Competitor Analysis - Product Thumbnail Image

DLL3-Targeted Immunotherapy: a Competitor Analysis

  • Report
  • May 2026
  • Global
From
Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 - Product Thumbnail Image

Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030

  • Report
  • November 2024
  • 600 Pages
  • Global
From
Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), Type (Diagnostic, Therapeutic), and Region with Growth Forecasts, 2025-2030 - Product Thumbnail Image

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), Type (Diagnostic, Therapeutic), and Region with Growth Forecasts, 2025-2030

  • Report
  • February 2025
  • 100 Pages
  • Global
From
Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type, By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type, By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • December 2024
  • 100 Pages
  • Global
From
Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast, 2021-2031 - Product Thumbnail Image

Radioligand Therapy Market - A Global and Regional Analysis: Focus on Indication, Product, Biomarker, and Region - Analysis and Forecast, 2021-2031

  • Report
  • March 2022
  • 182 Pages
  • Global
From
Neuroendocrine Carcinoma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Neuroendocrine Carcinoma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • June 2024
  • 200 Pages
  • Global
From
Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 - Product Thumbnail Image

Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027

  • Report
  • June 2023
  • 119 Pages
  • Global
From
Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition - Product Thumbnail Image

Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition

  • Report
  • March 2023
  • 117 Pages
  • Global
From
Gastric Neuroendocrine Tumors - Pipeline Insight, 2025 - Product Thumbnail Image

Gastric Neuroendocrine Tumors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Pipeline Insight, 2025 - Product Thumbnail Image

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Advanced Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Endothelial PAS Domain-containing Protein 1 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Endothelial PAS Domain-containing Protein 1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Merkel Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 90 Pages
  • Global
From
Atypical Teratoid Rhabdoid Tumors (ATRT)- Pipeline Insight, 2025 - Product Thumbnail Image

Atypical Teratoid Rhabdoid Tumors (ATRT)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Carcinoid Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Carcinoid Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Neuroendocrine Tumors - Market Insight, Epidemiology and Market Forecast - 2034

  • Drug Pipelines
  • September 2024
  • 247 Pages
  • Global
From
Loading Indicator

Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence. The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more